Which other medications interact with clopidogrel?

Clopidogrel Drug Interactions

Clopidogrel interacts with multiple medication classes that can either reduce its antiplatelet effectiveness or increase bleeding risk, most notably proton pump inhibitors (especially omeprazole), CYP2C19 inhibitors, anticoagulants, NSAIDs, SSRIs/SNRIs, and certain statins. 1

Medications That Reduce Clopidogrel Effectiveness

Proton Pump Inhibitors (PPIs)

• Omeprazole shows the strongest interaction with clopidogrel, reducing active metabolite levels and antiplatelet effects 2, 3
• However, the COGENT trial demonstrated that omeprazole reduced GI bleeding by 60% without increasing cardiovascular events (HR 0.99; 95% CI 0.68-1.44), suggesting the pharmacodynamic interaction may not translate to clinically meaningful harm 3
• Dexlansoprazole shows the least interaction among PPIs 1
• Despite laboratory evidence of reduced platelet inhibition, PPIs should not be withheld from patients with appropriate GI bleeding risk (prior GI bleeding, multiple risk factors including advanced age, concurrent anticoagulants/steroids/NSAIDs) 2

CYP2C19 Inhibitors

Clopidogrel requires CYP2C19 for conversion to its active metabolite. Inhibitors reduce this conversion 1:

• Strong inhibitors decrease active metabolite exposure and platelet inhibition
• Consider alternative antiplatelet agents (prasugrel, ticagrelor) in patients requiring strong CYP2C19 inhibitors

Lipophilic Statins

• Atorvastatin and simvastatin may competitively inhibit CYP3A4-mediated clopidogrel activation 3
• Laboratory studies show reduced platelet inhibition, but observational studies and randomized trials show conflicting results on clinical outcomes 4
• Statins should not be withheld due to concerns about clopidogrel interaction, as their cardiovascular benefits are well-established 4

Opioids

• Morphine (5 mg IV) decreased clopidogrel active metabolite AUC and Cmax by 34% 1
• Mean platelet aggregation was higher for 2-4 hours with morphine co-administration
• Consider this interaction in acute coronary syndrome patients receiving morphine for pain control

Medications That Increase Clopidogrel Effectiveness

CYP2C19 Inducers

• Rifampin (300 mg twice daily) increased active metabolite exposure 3.8-fold and platelet inhibition by 34% 1
• This may increase bleeding risk when co-administered

Medications That Increase Bleeding Risk

Anticoagulants

• Warfarin, heparin, and enoxaparin significantly increase bleeding risk when combined with clopidogrel 1
• Dual therapy requires careful risk-benefit assessment

NSAIDs and Aspirin

• All increase GI bleeding risk 2
• Risk increases with number of concurrent risk factors (advanced age, prior GI bleeding, H. pylori infection)
• Aspirin plus clopidogrel is appropriate for specific indications (ACS, post-PCI) but increases major bleeding from 2.7% to 3.7% 2

SSRIs and SNRIs

• Increase bleeding risk through platelet serotonin depletion 1
• Monitor closely for bleeding complications when co-prescribed

Medications Affected by Clopidogrel

Repaglinide

• Clopidogrel's glucuronide metabolite strongly inhibits CYP2C8 1
• Increases repaglinide exposure 5.1-fold after loading dose and 3.9-fold at maintenance dose 1
• Monitor for hypoglycemia and consider dose reduction of repaglinide

Clinical Management Algorithm

1. Before initiating clopidogrel: Review all concurrent medications for potential interactions 1

2. For patients requiring PPIs:

   • Use PPI if prior GI bleeding or multiple risk factors present 2
   • Prefer dexlansoprazole or pantoprazole over omeprazole if concerned about interaction 1
   • Do not withhold PPI based solely on interaction concerns 3

3. For patients on statins:

   • Continue statin therapy regardless of clopidogrel use 4
   • No dose adjustment needed

4. For patients requiring anticoagulation:

   • Carefully weigh thrombotic vs. bleeding risk
   • Consider alternative antiplatelet agents if triple therapy needed

5. Avoid stopping clopidogrel abruptly: Increases risk of heart attack or death 1

   • If surgery planned, discuss with prescribing physician
   • Generally stop at least 5 days before elective surgery 1

Important Caveats

• CYP2C19 poor metabolizers (2% of Whites, 4% of Blacks, 14% of Chinese) have reduced clopidogrel effectiveness regardless of drug interactions 1
• Most drug interaction studies show laboratory changes in platelet function that have not consistently translated to adverse clinical outcomes 4
• Individual patient factors (genetics, comorbidities, concurrent medications) create significant variability in clopidogrel response 3